BMC Cancer：司美替尼联合达卡巴嗪用于转移性葡萄膜黑色素瘤的临床研究

2015-06-14 范伟译 MedSci原创

背景：葡萄膜黑色素瘤的特点是GNAQ和GNA11突变，导致Ras /Raf/ MEK / ERK通路激活。司美替尼(AZD6244，ARRY-142886)MEK1/2抑制剂，其对葡萄膜黑色素瘤的临床前模型研究中有抗肿瘤效应。针对转移性葡萄膜黑色素瘤的患者以司美替尼单药治疗对比替莫唑胺或达卡巴嗪化疗，随机II期临床试验表明有改善的无进展生存期(PFS)和反应率(RR)。临床前，司美替尼联合烷基化试

背景：葡萄膜黑色素瘤的特点是GNAQ和GNA11突变，导致Ras /Raf/ MEK / ERK通路激活。司美替尼(AZD6244，ARRY-142886)MEK1/2抑制剂，其对葡萄膜黑色素瘤的临床前模型研究中有抗肿瘤效应。针对转移性葡萄膜黑色素瘤的患者以司美替尼单药治疗对比替莫唑胺或达卡巴嗪化疗，随机II期临床试验表明有改善的无进展生存期(PFS)和反应率(RR)。临床前，司美替尼联合烷基化试剂相比于单独化疗增强了抗肿瘤活性。我们假设司美替尼联合达卡巴嗪相比于单独使用达卡巴嗪针对转移性葡萄膜黑色素瘤患者将提高临床治疗效果。

方法/设计：SUMIT是一个随机的、国际双盲、安慰剂对照的，III期临床研究，评估司美替尼联合达卡巴嗪用于没有接受先前系统性治疗转移性葡萄膜黑色素瘤患者的有效性和安全性。主要终点是无进展生存期PFS。次要终点包括客观反应率RR、持续反应时间、第6周肿瘤大小的变化，总体生存期，安全性和耐受性。探索性终点包括GNAQ或GNA11突变肿瘤的功效。符合条件的患者必须有：≥1处病变，可以准确通过基线测量，以及适用于精确重复的测量；ECOG性能状态0 - 1，预期寿命> 12周。GNAQ/ GNA11的突变状态将进行回顾性评估。全世界50处网点约128名患者将随机(3:1)给以司美替尼每天两次75毫克或安慰剂联合达卡巴嗪1000mg/m2每21天周期的第一天，直到目标疾病进展、无法忍受毒性或另一个中止标准的发生。随机将通过有/没有肝转移存在进行分层。在每6周里通过RECIST v1.1对肿瘤进行评估。对所有的病人在疾病进展期可以选择接受司美替尼联合或不联合使用达卡巴嗪。研究招募开始于2014年4月，预计将在2015年初完成。

讨论：转移性葡萄膜黑色素瘤的治疗代表着较高未满足的医疗需求。本研究评估司美替尼联合达卡巴嗪的设计来自美国食品药品监督管理局，是第一个用于转移性葡萄膜黑色素瘤患者治疗的有潜力的注册试验。

此前的研究结果：Lancet Oncol：司美替尼+达卡巴嗪对黑色素瘤更有益

原始出处：

Carvajal RD, Schwartz GK, Mann H, Smith I, Nathan PD.Study design and rationale for a randomised, placebocontrolled, doubleblind study to assess the efficacy of selumetinib (AZD6244; ARRY142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).BMC Cancer. 2015 Jun 10;15:467. doi: 10.1186/s12885-015-1470-z.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (11)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=193505, encodeId=658e193505d2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu May 04 06:26:56 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680296, encodeId=e85d168029695, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Aug 10 18:26:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967130, encodeId=4795196e13005, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93919, encryptionId=43e293919b1, topicName=达卡巴嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 01 06:26:00 CST 2015, time=2015-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645382, encodeId=5c111645382f7, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93437, encryptionId=23929343ee9, topicName=转移性葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c6123209017, createdName=yeye5224620, createdTime=Fri Feb 26 16:26:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974613, encodeId=0c2d19e461370, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Jun 28 09:26:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29364, encodeId=b2402936410, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:38:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386163, encodeId=c1a8138616381, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425939, encodeId=b61114259394e, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4394020991, createdName=360611841, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558711, encodeId=ccc81558e11f3, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564720, encodeId=03001564e20a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
2017-05-04 1e145228m78(暂无匿称)

学习了，谢谢作者分享!

61 0
[GetPortalCommentsPageByObjectIdResponse(id=193505, encodeId=658e193505d2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu May 04 06:26:56 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680296, encodeId=e85d168029695, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Aug 10 18:26:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967130, encodeId=4795196e13005, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93919, encryptionId=43e293919b1, topicName=达卡巴嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 01 06:26:00 CST 2015, time=2015-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645382, encodeId=5c111645382f7, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93437, encryptionId=23929343ee9, topicName=转移性葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c6123209017, createdName=yeye5224620, createdTime=Fri Feb 26 16:26:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974613, encodeId=0c2d19e461370, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Jun 28 09:26:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29364, encodeId=b2402936410, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:38:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386163, encodeId=c1a8138616381, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425939, encodeId=b61114259394e, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4394020991, createdName=360611841, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558711, encodeId=ccc81558e11f3, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564720, encodeId=03001564e20a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
2015-08-10 sunylz

#色素#

24 0
[GetPortalCommentsPageByObjectIdResponse(id=193505, encodeId=658e193505d2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu May 04 06:26:56 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680296, encodeId=e85d168029695, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Aug 10 18:26:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967130, encodeId=4795196e13005, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93919, encryptionId=43e293919b1, topicName=达卡巴嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 01 06:26:00 CST 2015, time=2015-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645382, encodeId=5c111645382f7, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93437, encryptionId=23929343ee9, topicName=转移性葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c6123209017, createdName=yeye5224620, createdTime=Fri Feb 26 16:26:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974613, encodeId=0c2d19e461370, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Jun 28 09:26:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29364, encodeId=b2402936410, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:38:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386163, encodeId=c1a8138616381, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425939, encodeId=b61114259394e, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4394020991, createdName=360611841, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558711, encodeId=ccc81558e11f3, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564720, encodeId=03001564e20a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
2015-10-01 huanbaofeng

#达卡巴嗪#

25 0
[GetPortalCommentsPageByObjectIdResponse(id=193505, encodeId=658e193505d2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu May 04 06:26:56 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680296, encodeId=e85d168029695, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Aug 10 18:26:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967130, encodeId=4795196e13005, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93919, encryptionId=43e293919b1, topicName=达卡巴嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 01 06:26:00 CST 2015, time=2015-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645382, encodeId=5c111645382f7, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93437, encryptionId=23929343ee9, topicName=转移性葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c6123209017, createdName=yeye5224620, createdTime=Fri Feb 26 16:26:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974613, encodeId=0c2d19e461370, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Jun 28 09:26:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29364, encodeId=b2402936410, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:38:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386163, encodeId=c1a8138616381, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425939, encodeId=b61114259394e, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4394020991, createdName=360611841, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558711, encodeId=ccc81558e11f3, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564720, encodeId=03001564e20a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
2016-02-26 yeye5224620

#转移性葡萄膜黑色素瘤#

40 0
[GetPortalCommentsPageByObjectIdResponse(id=193505, encodeId=658e193505d2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu May 04 06:26:56 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680296, encodeId=e85d168029695, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Aug 10 18:26:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967130, encodeId=4795196e13005, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93919, encryptionId=43e293919b1, topicName=达卡巴嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 01 06:26:00 CST 2015, time=2015-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645382, encodeId=5c111645382f7, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93437, encryptionId=23929343ee9, topicName=转移性葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c6123209017, createdName=yeye5224620, createdTime=Fri Feb 26 16:26:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974613, encodeId=0c2d19e461370, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Jun 28 09:26:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29364, encodeId=b2402936410, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:38:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386163, encodeId=c1a8138616381, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425939, encodeId=b61114259394e, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4394020991, createdName=360611841, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558711, encodeId=ccc81558e11f3, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564720, encodeId=03001564e20a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
2015-06-28 ms3025846204744509

#BMC#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=193505, encodeId=658e193505d2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu May 04 06:26:56 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680296, encodeId=e85d168029695, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Aug 10 18:26:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967130, encodeId=4795196e13005, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93919, encryptionId=43e293919b1, topicName=达卡巴嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 01 06:26:00 CST 2015, time=2015-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645382, encodeId=5c111645382f7, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93437, encryptionId=23929343ee9, topicName=转移性葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c6123209017, createdName=yeye5224620, createdTime=Fri Feb 26 16:26:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974613, encodeId=0c2d19e461370, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Jun 28 09:26:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29364, encodeId=b2402936410, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:38:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386163, encodeId=c1a8138616381, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425939, encodeId=b61114259394e, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4394020991, createdName=360611841, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558711, encodeId=ccc81558e11f3, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564720, encodeId=03001564e20a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
2015-06-25 huaxipanxing

看看

109 0
[GetPortalCommentsPageByObjectIdResponse(id=193505, encodeId=658e193505d2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu May 04 06:26:56 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680296, encodeId=e85d168029695, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Aug 10 18:26:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967130, encodeId=4795196e13005, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93919, encryptionId=43e293919b1, topicName=达卡巴嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 01 06:26:00 CST 2015, time=2015-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645382, encodeId=5c111645382f7, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93437, encryptionId=23929343ee9, topicName=转移性葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c6123209017, createdName=yeye5224620, createdTime=Fri Feb 26 16:26:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974613, encodeId=0c2d19e461370, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Jun 28 09:26:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29364, encodeId=b2402936410, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:38:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386163, encodeId=c1a8138616381, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425939, encodeId=b61114259394e, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4394020991, createdName=360611841, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558711, encodeId=ccc81558e11f3, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564720, encodeId=03001564e20a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
2015-06-16 1249842em09(暂无昵称)

#转移性#

29 0
[GetPortalCommentsPageByObjectIdResponse(id=193505, encodeId=658e193505d2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu May 04 06:26:56 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680296, encodeId=e85d168029695, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Aug 10 18:26:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967130, encodeId=4795196e13005, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93919, encryptionId=43e293919b1, topicName=达卡巴嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 01 06:26:00 CST 2015, time=2015-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645382, encodeId=5c111645382f7, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93437, encryptionId=23929343ee9, topicName=转移性葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c6123209017, createdName=yeye5224620, createdTime=Fri Feb 26 16:26:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974613, encodeId=0c2d19e461370, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Jun 28 09:26:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29364, encodeId=b2402936410, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:38:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386163, encodeId=c1a8138616381, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425939, encodeId=b61114259394e, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4394020991, createdName=360611841, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558711, encodeId=ccc81558e11f3, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564720, encodeId=03001564e20a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
2015-06-16 360611841

#葡萄膜黑色素瘤#

31 0
[GetPortalCommentsPageByObjectIdResponse(id=193505, encodeId=658e193505d2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu May 04 06:26:56 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680296, encodeId=e85d168029695, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Aug 10 18:26:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967130, encodeId=4795196e13005, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93919, encryptionId=43e293919b1, topicName=达卡巴嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 01 06:26:00 CST 2015, time=2015-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645382, encodeId=5c111645382f7, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93437, encryptionId=23929343ee9, topicName=转移性葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c6123209017, createdName=yeye5224620, createdTime=Fri Feb 26 16:26:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974613, encodeId=0c2d19e461370, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Jun 28 09:26:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29364, encodeId=b2402936410, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:38:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386163, encodeId=c1a8138616381, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425939, encodeId=b61114259394e, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4394020991, createdName=360611841, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558711, encodeId=ccc81558e11f3, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564720, encodeId=03001564e20a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
2015-06-16 cqlidoudou

#黑色素#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=193505, encodeId=658e193505d2, content=学习了，谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu May 04 06:26:56 CST 2017, time=2017-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680296, encodeId=e85d168029695, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Mon Aug 10 18:26:00 CST 2015, time=2015-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967130, encodeId=4795196e13005, content=<a href='/topic/show?id=43e293919b1' target=_blank style='color:#2F92EE;'>#达卡巴嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93919, encryptionId=43e293919b1, topicName=达卡巴嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e729101, createdName=huanbaofeng, createdTime=Thu Oct 01 06:26:00 CST 2015, time=2015-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645382, encodeId=5c111645382f7, content=<a href='/topic/show?id=23929343ee9' target=_blank style='color:#2F92EE;'>#转移性葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93437, encryptionId=23929343ee9, topicName=转移性葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c6123209017, createdName=yeye5224620, createdTime=Fri Feb 26 16:26:00 CST 2016, time=2016-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974613, encodeId=0c2d19e461370, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Jun 28 09:26:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29364, encodeId=b2402936410, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:38:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386163, encodeId=c1a8138616381, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425939, encodeId=b61114259394e, content=<a href='/topic/show?id=588988285e6' target=_blank style='color:#2F92EE;'>#葡萄膜黑色素瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88285, encryptionId=588988285e6, topicName=葡萄膜黑色素瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4394020991, createdName=360611841, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558711, encodeId=ccc81558e11f3, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564720, encodeId=03001564e20a1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Tue Jun 16 12:26:00 CST 2015, time=2015-06-16, status=1, ipAttribution=)]
2015-06-16 cqlidoudou

#黑色素#

26 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

BMC Cancer：司美替尼联合达卡巴嗪用于转移性葡萄膜黑色素瘤的临床研究

相关资讯

科室

工具

服务

肿瘤科

BMC Cancer：司美替尼联合达卡巴嗪用于转移性葡萄膜黑色素瘤的临床研究

相关资讯

阿斯利康开展司美替尼用于NSCLC的III期临床研究

JAMA：司美替尼（selumetinib）对葡萄膜黑色素瘤的治疗优于化疗

Lancer Oncol：司美替尼对复发的卵巢低分化鳞癌有效

科室

工具

服务